Maximizing gene therapy
At Infirmacea, we are dedicated to developing safe, effective, and affordable gene therapy options for a healthier future. Our mission is to transform gene therapies into innovative solutions that improve health span.
gBoostTM: Powering Precision Gene Therapy
Our innovative technology, gBoostTM, redefines the potential of gene therapy. Designed to enhance gene expression, gBoostTM offers two remarkable features: (1) Versatile compatibility: It boosts gene expression regardless of the vectors or delivery method—viral or non-viral. (2) Cell selectivity: Effect of gBoostTM is cell type dependent. Its mechanism is to minimize cellular response triggered by gene entry into cells, rather than relying on conventional gene delivery enhancers, which mainly accelerate cell-selective uptake of genes. This makes gBoostTM effective even with delivery-engineered vectors. Composed of clinically safe materials, gBoostTM is intended for use as an excipient in gene therapy products. To maximize its impact, gBoostTM is optimized for specific target cells and gene delivery systems, including viral serotypes. Tailor gBoostTM to your unique needs by contacting us today.
DNA therapy:
Revolutionizing Health with Fat-Directed DNA Therapy
At Infirmacea, we are pioneering an innovative DNA therapy platform designed to transform subcutaneous fat into a “health engine” for promoting disease resistance. Utilizing plasmid DNAs—a safe and affordable material—enhanced by our proprietary gBoost™ excipient and delivered with electronic pulses (electrotransfer), this groundbreaking approach redefines the potential of fat-directed DNA therapy. Subcutaneous fat becomes a source of therapeutic proteins or a controller of metabolism and inflammation, unlocking new possibilities for health. Our primary focus is addressing muscle weakness, including conditions such as sarcopenic obesity, frailty, and sarcopenia. Muscle loss is a common challenge, particularly in aging populations and patients undergoing weight-loss treatments like GLP-1 agonists. Muscle weakness contributes to poor health outcomes, yet no effective therapies exist to preserve muscle mass and strength—aside from exercise, which is not always a viable option. By developing therapeutic solutions to maintain healthy muscle mass and functionality, we aim to empower individuals to age with vitality and resilience. With plans to expand further into the anti-aging space, Infirmacea is shaping a future where health, strength, and well-being define every stage of life.
exFat: Your Window into Human Biology
Our ex vivo human fat culture platform, exFat, provides a unique opportunity to study real human responses to therapeutic interventions. Enabled by our proprietary culture device, exFat maintains the activity of human fat tissue for up to one month, offering unprecedented insights into therapeutic development. Sourced ethically from surgical waste, exFat serves as a powerful tool for advancing our DNA therapy platform. By analyzing the responses of fat tissue—comprised of diverse cell types such as immune cells, progenitors, blood vessels, neurons, and fat cells—we can better predict the efficacy and safety of therapies in humans. This approach has the potential to enhance clinical trial success rates by providing more accurate preclinical insights. Beyond its application in DNA therapy, fat tissue itself holds valuable information for anti-aging research. As fat plays a central role in aging processes, analyzing fat across different ages allows us to uncover both adaptive changes and the critical factors that trigger age-related transformations. These efforts represent our long-term vision and investment in developing a future anti-aging pipeline. With exFat, we are unlocking the secrets of fat tissue to drive breakthroughs in health, longevity, and anti-aging innovation.
